Biotech RadarJobs updated

COMPANY

ReCode Therapeutics

HQ: Menlo Park, CA source · recodetx.com ↗ · West Coast

Clinical Phase 2

1 open job · last seen Oct 24, 2026 · 7 sources

Keywords: cystic fibrosis primary ciliary dyskinesia RCT2100 RCT1100 Sano Genetics Testing Kit

Location: Menlo Park, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

1Open jobs6Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Join Our Talent CommunityMenlo Park, California, United StatesApr 25, 2024Oct 8, 2026

See all 1 job

Raises and deals from press releases

Raises announced in these releases: $29M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

  1. Board tracked Radar started tracking this company’s job board (1 open job at last check). source ↗
  2. Raise Undisclosed round · more than $29M source ↗
  3. Trial start Phase 1: Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance source ↗
  4. Trial start Phase 1: A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults With PCD source ↗
  5. Trial start 2: A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF source ↗
  6. Trial start —: A Study Providing Genetic Testing to Find Those Who May Have Primary Ciliary Dyskinesia for Potential Clinical Trials source ↗
  7. Trial start —: A Longitudinal, Observational Study of Primary Ciliary Dyskinesia in Adults source ↗
  8. Trial start Phase 1: Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 1

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Join Our Talent CommunityMenlo Park, California, United StatesApr 25, 2024Oct 8, 2026Not stated

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Clinical trials (lead sponsor) 6

RecordTitlePhaseStatusStartPrimary completion
NCT06237335A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF2Active, not recruitingFeb 1, 20242026-11 (estimated)
NCT05685186A Longitudinal, Observational Study of Primary Ciliary Dyskinesia in AdultsNot listedCompletedMar 8, 2023Apr 28, 2025 (actual)
NCT06633757Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary ClearancePhase 1CompletedOct 22, 2024Jun 30, 2025 (actual)
NCT06600425A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults With PCDPhase 1CompletedSep 20, 2024Jun 6, 2025 (actual)
NCT06172374A Study Providing Genetic Testing to Find Those Who May Have Primary Ciliary Dyskinesia for Potential Clinical TrialsNot listedActive, not recruitingAug 31, 2023Apr 30, 2025 (actual)
NCT05737485Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD SubjectsPhase 1CompletedFeb 18, 2023Jul 25, 2024 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Connect

See your connections at ReCode Therapeutics on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback